by Clinical Neuropsychologist Online | Sunday, October 6, 2024 | Dementia
Abstract INTRODUCTION Growing evidence suggests a role for neuroinflammation in Alzheimer’s disease (AD). We investigated complement pathway activity in AD patient cerebrospinal fluid (CSF) and evaluated its modulation by the anti-tau antibody semorinemab....
by Clinical Neuropsychologist Online | Sunday, October 6, 2024 | Neurorehabilitation
Volume 27, Issue 8, November 2024, Page 311-319. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: A. J. Hilderley D. Fehlings M. J. Taylor J. L. Chen F. V....
by Clinical Neuropsychologist Online | Sunday, October 6, 2024 | Dementia
Abstract A brief history of events surrounding the conceptualization and original implementation of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) as a public–private partnership (PPP) is provided from the perspective of three individuals directly...
by Clinical Neuropsychologist Online | Sunday, October 6, 2024 | Dementia
Abstract Diagnosing Alzheimer’s disease (AD) poses significant challenges to health care, often resulting in delayed or inadequate patient care. The clinical integration of blood-based biomarkers (BBMs) for AD holds promise in enabling early detection of...
by Clinical Neuropsychologist Online | Sunday, October 6, 2024 | Dementia
Abstract INTRODUCTION We evaluated the efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer’s dementia (AAD) in Japanese patients. METHODS This was a phase 2/3 multicenter, randomized, double-blind, placebo-controlled, parallel-group...
